- Home
- DRMA vs IMTE Comparison
DRMA vs IMTE Comparison
Compare DRMA & IMTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- IMTE
- Stock Information
- Founded
- DRMA 2014
- IMTE 2008
- Country
- DRMA United States
- IMTE Malaysia
- Employees
- DRMA N/A
- IMTE N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- IMTE Consumer Electronics/Appliances
- Sector
- DRMA Health Care
- IMTE Consumer Staples
- Exchange
- DRMA Nasdaq
- IMTE Nasdaq
- Market Cap
- DRMA 3.6M
- IMTE 3.3M
- IPO Year
- DRMA 2021
- IMTE N/A
- Fundamental
- Price
- DRMA $5.57
- IMTE $1.16
- Analyst Decision
- DRMA Strong Buy
- IMTE
- Analyst Count
- DRMA 1
- IMTE 0
- Target Price
- DRMA $10.00
- IMTE N/A
- AVG Volume (30 Days)
- DRMA 27.3K
- IMTE 66.4K
- Earning Date
- DRMA 08-13-2025
- IMTE 10-21-2025
- Dividend Yield
- DRMA N/A
- IMTE N/A
- EPS Growth
- DRMA N/A
- IMTE N/A
- EPS
- DRMA N/A
- IMTE N/A
- Revenue
- DRMA N/A
- IMTE $123,337.00
- Revenue This Year
- DRMA N/A
- IMTE N/A
- Revenue Next Year
- DRMA N/A
- IMTE N/A
- P/E Ratio
- DRMA N/A
- IMTE N/A
- Revenue Growth
- DRMA N/A
- IMTE 4.75
- 52 Week Low
- DRMA $5.04
- IMTE $0.51
- 52 Week High
- DRMA $24.90
- IMTE $3.17
- Technical
- Relative Strength Index (RSI)
- DRMA 45.37
- IMTE 65.50
- Support Level
- DRMA $5.04
- IMTE $0.87
- Resistance Level
- DRMA $5.74
- IMTE $1.04
- Average True Range (ATR)
- DRMA 0.39
- IMTE 0.11
- MACD
- DRMA 0.03
- IMTE 0.03
- Stochastic Oscillator
- DRMA 48.91
- IMTE 86.44
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About IMTE Integrated Media Technology Limited
Integrated Media Technology Ltd is engaged in the development, sale, and distribution of autostereoscopic 3D display, 3D conversion equipment, and software, development, and sale of 3D autostereoscopic technology, and the provision of 3D consultancy services. It operates through the following segments: the sale of electronic glass, sales of air-filter products, sales of Halal products, NFT, corporate, provision of consultancy and provision of new energy products and solutions.